Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

February 2022 | 59 pages | ID: HDA61EDB0DABEN
Global Markets Direct

Abstracts

Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape.

Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood. Symptoms include disorientation, drowsiness, or confusion, change in sleep patterns, slurred speech and agitation, excitement, or seizures (occur rarely). The predisposing factors include gastrointestinal bleeding, increased protein intake, renal dysfunction with azotemia, constipation (due to increased nitrogen load), drugs (particularly sedatives and diuretics) and hypoxia.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatic Encephalopathy (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 8, 4 and 3 respectively.

Hepatic Encephalopathy (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hepatic Encephalopathy (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hepatic Encephalopathy (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hepatic Encephalopathy (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hepatic Encephalopathy (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Hepatic Encephalopathy - Overview
Hepatic Encephalopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hepatic Encephalopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatic Encephalopathy - Companies Involved in Therapeutics Development
Alfasigma SpA
Axcella Health Inc
Cosmo Pharmaceuticals NV
Grifols SA
Kaleido Biosciences Inc
Neuropathix Inc
Rebiotix Inc
Takeda Pharmaceutical Co Ltd
TenNor Therapeutics Ltd
Umecrine Cognition AB
Vedanta Biosciences Inc
Versantis AG
Hepatic Encephalopathy - Drug Profiles
albumin (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
AXA-1665 - Drug Profile
Product Description
Mechanism Of Action
History of Events
golexanolone - Drug Profile
Product Description
Mechanism Of Action
History of Events
KB-174 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KLS-13019 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KLS-13023 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RBX-2660 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RBX-7455 - Drug Profile
Product Description
Mechanism Of Action
History of Events
rifamycin sodium CR - Drug Profile
Product Description
Mechanism Of Action
History of Events
rifaximin - Drug Profile
Product Description
Mechanism Of Action
History of Events
rifaximin SSD - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAK-039 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TNP-2092 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VE-303 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VS-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VS-02 - Drug Profile
Product Description
Mechanism Of Action
Hepatic Encephalopathy - Dormant Projects
Hepatic Encephalopathy - Discontinued Products
Hepatic Encephalopathy - Product Development Milestones
Featured News & Press Releases
Jan 18, 2022: Neuropathix receives patent grant from India for its novel anti-inflammatory compounds
Jan 11, 2022: Karolinska Development's portfolio company Umecrine Cognition presents preclinical data showing that golexanolone reduces neuroinflammation and counteracts motor symptoms
Nov 02, 2021: Axcella Therapeutics announces upcoming presentation of AXA1665 at AASLD’s The Liver Meeting 2021
Jul 14, 2021: Karolinska Development’s portfolio company Umecrine Cognition raises capital through a successful share issue
Jun 30, 2021: Axcella announces initiation of EMMPOWER phase 2 clinical trial of AXA1665
May 24, 2021: Positive clinical data about Axcella’s AXA1665 candidate for overt hepatic encephalopathy highlighted in oral presentation at DDW 2021
Apr 22, 2021: Axcella announces upcoming oral presentation at digestive disease week (ddw) 2021
Apr 22, 2021: Karolinska Development's portfolio company Umecrine Cognition publishes clinical research results in a highly regarded journal
Dec 29, 2020: Karolinska Development increases book value of Umecrine Cognition by SEK 234 million
Oct 07, 2020: Kaleido Biosciences to present data from candidate KB174 at The Liver Meeting 2020
Oct 06, 2020: Kannalife adds to its global IP estate receiving patent grant from Canada for its novel anti-inflammatory compounds
Sep 02, 2020: Karolinska Development’s portfolio company Umecrine Cognition presents results from clinical phase 2a study at AALSD International Liver meeting
Aug 27, 2020: Kaleido Biosciences announces presentation of data for microbiome metabolic therapy KB174 for Hepatic Encephalopathy at The Digital International Liver Congress (EASL)
Aug 25, 2020: Kannalife receives patent grants in additional European territories
Aug 05, 2020: Axcella reports positive top-line data from AXA1665-002
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hepatic Encephalopathy, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hepatic Encephalopathy - Pipeline by Alfasigma SpA, 2022
Hepatic Encephalopathy - Pipeline by Axcella Health Inc, 2022
Hepatic Encephalopathy - Pipeline by Cosmo Pharmaceuticals NV, 2022
Hepatic Encephalopathy - Pipeline by Grifols SA, 2022
Hepatic Encephalopathy - Pipeline by Kaleido Biosciences Inc, 2022
Hepatic Encephalopathy - Pipeline by Neuropathix Inc, 2022
Hepatic Encephalopathy - Pipeline by Rebiotix Inc, 2022
Hepatic Encephalopathy - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Hepatic Encephalopathy - Pipeline by TenNor Therapeutics Ltd, 2022
Hepatic Encephalopathy - Pipeline by Umecrine Cognition AB, 2022
Hepatic Encephalopathy - Pipeline by Vedanta Biosciences Inc, 2022
Hepatic Encephalopathy - Pipeline by Versantis AG, 2022
Hepatic Encephalopathy - Dormant Projects, 2022
Hepatic Encephalopathy - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hepatic Encephalopathy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022